Oliwia Zdanowska
Research Subjects
Oliwia Zdanowska has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Monika Modrzejewska
2nd Department of Ophthalmology, Pomeranian Medical University in Szczecin, 70-111 Szczecin, Poland
10 shared publications - Piotr Połubiński
Scientific Association of Students, 2nd Department of Ophthalmology, Pomeranian Medical University in Szczecin, Powstańców Wielkopolskich 72, 70-111 Szczecin, Poland
4 shared publications - Wiktoria Bosy-Gąsior
Scientific Association of Students 2nd Department of Ophthalmology, Pomeranian Medical University in Szczecin, Powstańców Wielkopolskich 72, 70-111 Szczecin, Poland
3 shared publications - Dawid Świstara
Szpital Uniwersytecki im. Karola Marcinkowskiego w Zielonej Górze, Polska
2 shared publications - Joanna Cyrankiewicz
SP ZOZ MSWiA, ul. Jagiellońska 44, 70-382 Szczecin, Poland
2 shared publications - Anna Modrzejewska
Department of Ophthalmology, Independent Public Healthcare Institution of the Ministry of the Interior and Administration, 70-382 Szczecin, Poland
1 shared publication
Latest Publications
- Open Access
- 13 October 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (20) , 7889
Variability in Refractive Measurements in Children with Autism Spectrum Disorder Under Cycloplegic and Non-Cycloplegic Conditions: Influence of Measurement Method
Purpose: To compare refractive measurements obtained with Retinomax K-plus 3 and Plusoptix A09 V in children with autism spectrum disorder (ASD) before and after cycloplegia and to assess inter-device agreement. Methods: This retrospective pilot study included 23 children with ASD (mean age 6.54 ± 2.83 years), of whom 14 underwent examination with two autorefractometers (Retinomax K-plus 3 and Plusoptix A09 V) before and after cycloplegia induced with 1% tropicamide. Direct inter-device comparisons were restricted to the 14 children with paired measurements and were performed using the Wilcoxon signed-rank test, with matched-pairs rank-biserial correlations reported as effect sizes. Agreement in spherical equivalent (SE) was assessed using Bland–Altman analysis. Cycloplegia-induced refractive shifts were compared between devices. Secondary comparisons with controls without documented neurodevelopmental disorders (n = 27) were restricted to Retinomax SE measurements and performed using analysis of covariance (ANCOVA), with age included as a continuous covariate. Results: Before cycloplegia, Retinomax showed significantly more myopic SE values than Plusoptix in both eyes (right eye [OD]: −1.21 ± 1.25 vs. 0.91 ± 0.67 D; left eye [OS]: −1.22 ± 1.15 vs. 0.77 ± 0.51 D; both p < 0.00417). Significant inter-device differences in SE persisted after cycloplegia (OD: 0.63 ± 0.94 vs. 2.00 ± 0.63 D; OS: 0.46 ± 0.96 vs. 1.98 ± 0.63 D; both p < 0.001). Bland–Altman analysis showed a systematic negative bias of Retinomax relative to Plusoptix, which decreased after cycloplegia but persisted (before: −2.12 D for OD and −1.99 D for OS; after: −1.37 D and −1.52 D, respectively). Cycloplegia-induced shifts were greater with Retinomax; however, the between-device differences were not statistically significant after Bonferroni correction. In secondary analyses, age-adjusted Retinomax SE remained significantly lower in the ASD group than in controls without documented neurodevelopmental disorders before and after cycloplegia (all p < 0.001). Conclusions: In this exploratory cohort of children with ASD, Retinomax measurements were associated with more myopic SE values than Plusoptix, particularly before cycloplegia. The inter-device bias decreased but persisted after cycloplegia. This reduction is compatible with a contribution of accommodation; however, the persistence of the bias after cycloplegia indicates that device-specific measurement characteristics should also be considered. Refractive measurements obtained with the two autorefractometers should therefore not be assumed to be directly interchangeable. These findings underscore the importance of cycloplegic control and careful interpretation of autorefractor measurements in children with ASD. Larger prospective studies are warranted.
- 13 October 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (20) , 7889
Open AccessVariability in Refractive Measurements in Children with Autism Spectrum Disorder Under Cycloplegic and Non-Cycloplegic Conditions: Influence of Measurement Method
Purpose: To compare refractive measurements obtained with Retinomax K-plus 3 and Plusoptix A09 V in children with autism spectrum disorder (ASD) before and after cycloplegia and to assess inter-device agreement. Methods: This retrospective pilot study included 23 children with ASD (mean age 6.54 ± 2.83 years), of whom 14 underwent examination with two autorefractometers (Retinomax K-plus 3 and Plusoptix A09 V) before and after cycloplegia induced with 1% tropicamide. Direct inter-device comparisons were restricted to the 14 children with paired measurements and were performed using the Wilcoxon signed-rank test, with matched-pairs rank-biserial correlations reported as effect sizes. Agreement in spherical equivalent (SE) was assessed using Bland–Altman analysis. Cycloplegia-induced refractive shifts were compared between devices. Secondary comparisons with controls without documented neurodevelopmental disorders (n = 27) were restricted to Retinomax SE measurements and performed using analysis of covariance (ANCOVA), with age included as a continuous covariate. Results: Before cycloplegia, Retinomax showed significantly more myopic SE values than Plusoptix in both eyes (right eye [OD]: −1.21 ± 1.25 vs. 0.91 ± 0.67 D; left eye [OS]: −1.22 ± 1.15 vs. 0.77 ± 0.51 D; both p < 0.00417). Significant inter-device differences in SE persisted after cycloplegia (OD: 0.63 ± 0.94 vs. 2.00 ± 0.63 D; OS: 0.46 ± 0.96 vs. 1.98 ± 0.63 D; both p < 0.001). Bland–Altman analysis showed a systematic negative bias of Retinomax relative to Plusoptix, which decreased after cycloplegia but persisted (before: −2.12 D for OD and −1.99 D for OS; after: −1.37 D and −1.52 D, respectively). Cycloplegia-induced shifts were greater with Retinomax; however, the between-device differences were not statistically significant after Bonferroni correction. In secondary analyses, age-adjusted Retinomax SE remained significantly lower in the ASD group than in controls without documented neurodevelopmental disorders before and after cycloplegia (all p < 0.001). Conclusions: In this exploratory cohort of children with ASD, Retinomax measurements were associated with more myopic SE values than Plusoptix, particularly before cycloplegia. The inter-device bias decreased but persisted after cycloplegia. This reduction is compatible with a contribution of accommodation; however, the persistence of the bias after cycloplegia indicates that device-specific measurement characteristics should also be considered. Refractive measurements obtained with the two autorefractometers should therefore not be assumed to be directly interchangeable. These findings underscore the importance of cycloplegic control and careful interpretation of autorefractor measurements in children with ASD. Larger prospective studies are warranted.
- Open Access
- 27 September 2024
- Published by Pomorski Uniwersytet Medyczny w Szczecinie in Pomeranian Journal of Life Sciences
- Vol. 70 (3)
Causes and contemporary epidemiology of pediatric uveitis – a current review of the literature
Uveitis is a group of diseases that are prevalent worldwide and can lead to serious ophthalmic complications that threaten vision. In the pediatric population, uveitis often presents as a systemic disease with a severe course. Early diagnosis of the causative disease entity for uveitis is often delayed due to the limited cooperation of pediatric patients. Although most cases of uveitis are idiopathic (40%), understanding the potential complications and multiorgan involvement facilitates multidisciplinary pediatric care and allows for earlier initiation of appropriate treatment, prevention and reduction of ocular complications, thus contributing to the normal development of the child. In the first part of this article, the authors reviewed the current literature (2018–2023) from PubMed and Google Scholar to present an updated perspective on the classification and causes of uveitis. Due to the lack of recent data on the prevalence of specific types of uveitis in the pediatric population in Poland, the authors referred to statistical analyses from 2001–2006.
- 27 September 2024
- Published by Pomorski Uniwersytet Medyczny w Szczecinie in Pomeranian Journal of Life Sciences
- Vol. 70 (3)
Open AccessCauses and contemporary epidemiology of pediatric uveitis – a current review of the literature
Uveitis is a group of diseases that are prevalent worldwide and can lead to serious ophthalmic complications that threaten vision. In the pediatric population, uveitis often presents as a systemic disease with a severe course. Early diagnosis of the causative disease entity for uveitis is often delayed due to the limited cooperation of pediatric patients. Although most cases of uveitis are idiopathic (40%), understanding the potential complications and multiorgan involvement facilitates multidisciplinary pediatric care and allows for earlier initiation of appropriate treatment, prevention and reduction of ocular complications, thus contributing to the normal development of the child. In the first part of this article, the authors reviewed the current literature (2018–2023) from PubMed and Google Scholar to present an updated perspective on the classification and causes of uveitis. Due to the lack of recent data on the prevalence of specific types of uveitis in the pediatric population in Poland, the authors referred to statistical analyses from 2001–2006.
- Open Access
- 10 July 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (14) , 4034
The Role of HIF-1α in Retinopathy of Prematurity: A Review of Current Literature
Hypoxia-inducible factor (HIF) plays a crucial role in regulating oxygen sensing and adaptation at the cellular level, overseeing cellular oxygen homeostasis, erythrocyte production, angiogenesis, and mitochondrial metabolism. The hypoxia-sensitive HIF-1α subunit facilitates tissue adaptation to hypoxic conditions, including the stimulation of proangiogenic factors. Retinopathy of prematurity (ROP) is a proliferative vascular disease of the retina that poses a significant risk to prematurely born children. If untreated, ROP can lead to retinal detachment, severe visual impairment, and even blindness. The pathogenesis of ROP is not fully understood; however, reports suggest that premature birth leads to the exposure of immature ocular tissues to high levels of exogenous oxygen and hyperoxia, which increase the synthesis of reactive oxygen species and inhibit HIF expression. During the ischemic phase, HIF-1α expression is stimulated in the hypoxia-sensitive retina, causing an overproduction of proangiogenic factors and the development of pathological neovascularization. Given the significant role of HIF-1α in the development of ROP, considering it as a potential molecular target for therapeutic strategies appears justified. This review synthesizes information from the last six years (2018–2024) using databases such as PubMed, Google Scholar, and BASE, focusing on the role of HIF-1α in the pathogenesis of ROP and its potential as a target for new therapies.
- 10 July 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (14) , 4034
Open AccessThe Role of HIF-1α in Retinopathy of Prematurity: A Review of Current Literature
Hypoxia-inducible factor (HIF) plays a crucial role in regulating oxygen sensing and adaptation at the cellular level, overseeing cellular oxygen homeostasis, erythrocyte production, angiogenesis, and mitochondrial metabolism. The hypoxia-sensitive HIF-1α subunit facilitates tissue adaptation to hypoxic conditions, including the stimulation of proangiogenic factors. Retinopathy of prematurity (ROP) is a proliferative vascular disease of the retina that poses a significant risk to prematurely born children. If untreated, ROP can lead to retinal detachment, severe visual impairment, and even blindness. The pathogenesis of ROP is not fully understood; however, reports suggest that premature birth leads to the exposure of immature ocular tissues to high levels of exogenous oxygen and hyperoxia, which increase the synthesis of reactive oxygen species and inhibit HIF expression. During the ischemic phase, HIF-1α expression is stimulated in the hypoxia-sensitive retina, causing an overproduction of proangiogenic factors and the development of pathological neovascularization. Given the significant role of HIF-1α in the development of ROP, considering it as a potential molecular target for therapeutic strategies appears justified. This review synthesizes information from the last six years (2018–2024) using databases such as PubMed, Google Scholar, and BASE, focusing on the role of HIF-1α in the pathogenesis of ROP and its potential as a target for new therapies.
- Open Access
- 30 June 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (13) , 3851
The Role of Heat Shock Protein 70 (HSP70) in the Pathogenesis of Ocular Diseases—Current Literature Review
Heat shock proteins (HSPs) have been attracting the attention of researchers for many years. HSPs are a family of ubiquitous, well-characterised proteins that are generally regarded as protective multifunctional molecules that are expressed in response to different types of cell stress. Their activity in many organs has been reported, including the heart, brain, and retina. By acting as chaperone proteins, HSPs help to refold denatured proteins. Moreover, HSPs elicit inhibitory activity in apoptotic pathways and inflammation. Heat shock proteins were originally classified into several subfamilies, including the HSP70 family. The aim of this paper is to systematise information from the available literature about the presence of HSP70 in the human eye and its role in the pathogenesis of ocular diseases. HSP70 has been identified in the cornea, lens, and retina of a normal eye. The increased expression and synthesis of HSP70 induced by cell stress has also been demonstrated in eyes with pathologies such as glaucoma, eye cancers, cataracts, scarring of the cornea, ocular toxpoplasmosis, PEX, AMD, RPE, and diabetic retinopathy. Most of the studies cited in this paper confirm the protective role of HSP70. However, little is known about these molecules in the human eye and their role in the pathogenesis of eye diseases. Therefore, understanding the role of HSP70 in the pathophysiology of injuries to the cornea, lens, and retina is essential for the development of new therapies aimed at limiting and/or reversing the processes that cause damage to the eye.
- 30 June 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (13) , 3851
Open AccessThe Role of Heat Shock Protein 70 (HSP70) in the Pathogenesis of Ocular Diseases—Current Literature Review
Heat shock proteins (HSPs) have been attracting the attention of researchers for many years. HSPs are a family of ubiquitous, well-characterised proteins that are generally regarded as protective multifunctional molecules that are expressed in response to different types of cell stress. Their activity in many organs has been reported, including the heart, brain, and retina. By acting as chaperone proteins, HSPs help to refold denatured proteins. Moreover, HSPs elicit inhibitory activity in apoptotic pathways and inflammation. Heat shock proteins were originally classified into several subfamilies, including the HSP70 family. The aim of this paper is to systematise information from the available literature about the presence of HSP70 in the human eye and its role in the pathogenesis of ocular diseases. HSP70 has been identified in the cornea, lens, and retina of a normal eye. The increased expression and synthesis of HSP70 induced by cell stress has also been demonstrated in eyes with pathologies such as glaucoma, eye cancers, cataracts, scarring of the cornea, ocular toxpoplasmosis, PEX, AMD, RPE, and diabetic retinopathy. Most of the studies cited in this paper confirm the protective role of HSP70. However, little is known about these molecules in the human eye and their role in the pathogenesis of eye diseases. Therefore, understanding the role of HSP70 in the pathophysiology of injuries to the cornea, lens, and retina is essential for the development of new therapies aimed at limiting and/or reversing the processes that cause damage to the eye.
- Open Access
Uveitis in the Pediatric Population and Therapeutic Management: A Current Literature Review
Uveitis is an inflammatory disease that can lead to severe complications, including vision loss. The pediatric population is particularly at risk of developing complications, as uveitis in this age group often has idiopathic origins or is associated with systemic diseases that follow a severe course. This, coupled with unfavorable treatment outcomes, continues to be a challenge in pediatric ophthalmology. The cornerstone of uveitis treatment involves a therapeutic strategy that depends on the etiology, severity, and localization of the inflammation, as well as the patient’s response to treatment and the presence of ocular complications. Patients who do not receive timely treatment face a significantly increased risk of experiencing a severe disease course. Understanding potential therapeutic options and their side effects is crucial in managing children with uveitis. Equally important is the continuous monitoring of the child’s condition throughout the treatment process, due to the chronic and recurrent nature of uveitis in this demographic. The authors conducted a review of the current literature from 2018 to 2023 on the management and introduction of new therapeutic approaches for children with uveitis.
Open AccessUveitis in the Pediatric Population and Therapeutic Management: A Current Literature Review
Uveitis is an inflammatory disease that can lead to severe complications, including vision loss. The pediatric population is particularly at risk of developing complications, as uveitis in this age group often has idiopathic origins or is associated with systemic diseases that follow a severe course. This, coupled with unfavorable treatment outcomes, continues to be a challenge in pediatric ophthalmology. The cornerstone of uveitis treatment involves a therapeutic strategy that depends on the etiology, severity, and localization of the inflammation, as well as the patient’s response to treatment and the presence of ocular complications. Patients who do not receive timely treatment face a significantly increased risk of experiencing a severe disease course. Understanding potential therapeutic options and their side effects is crucial in managing children with uveitis. Equally important is the continuous monitoring of the child’s condition throughout the treatment process, due to the chronic and recurrent nature of uveitis in this demographic. The authors conducted a review of the current literature from 2018 to 2023 on the management and introduction of new therapeutic approaches for children with uveitis.
- Open Access
- 21 June 2024
- Published by Pomorski Uniwersytet Medyczny w Szczecinie in Pomeranian Journal of Life Sciences
- Vol. 70 (2)
Current diagnostic options in uveitis – a review of the literature
Most cases of uveitis in the pediatric population with an identifiable etiology are non-infectious (67.2–93.8%) and occur in the setting of severe systemic disease. Collaboration among physicians of different specialties and a wide range of specialized diagnostic tests are essential in determining the correct diagnosis of the disease entity. Children are at greater risk of developing serious ophthalmic complications that can threaten vision, interfere with normal childhood development, and lead to severe disability. Therefore, it is important to diagnose the disease at an early stage. A reliable diagnosis allows the implementation of appropriate therapy, which can prevent the occurrence of further complications. The authors of this study reviewed the current literature (2018–2023) in PubMed and Google Scholar, outlining the current diagnostic options for uveitis.
- 21 June 2024
- Published by Pomorski Uniwersytet Medyczny w Szczecinie in Pomeranian Journal of Life Sciences
- Vol. 70 (2)
Open AccessCurrent diagnostic options in uveitis – a review of the literature
Most cases of uveitis in the pediatric population with an identifiable etiology are non-infectious (67.2–93.8%) and occur in the setting of severe systemic disease. Collaboration among physicians of different specialties and a wide range of specialized diagnostic tests are essential in determining the correct diagnosis of the disease entity. Children are at greater risk of developing serious ophthalmic complications that can threaten vision, interfere with normal childhood development, and lead to severe disability. Therefore, it is important to diagnose the disease at an early stage. A reliable diagnosis allows the implementation of appropriate therapy, which can prevent the occurrence of further complications. The authors of this study reviewed the current literature (2018–2023) in PubMed and Google Scholar, outlining the current diagnostic options for uveitis.
- Open Access
- 8 June 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (12) , 3379
Ophthalmic Complications, Diagnosis, and Treatment of Congenital Human Cytomegalovirus Infection
Background: Human cytomegalovirus (hCMV) is the most common etiological agent of congenital infections seen in newborns. Among the most commonly observed complications in children with congenital human cytomegalovirus infection are those affecting the visual system. Ocular complications of congenital CMV (cCMV) are a topic rarely addressed in the literature, which prompted the authors to update the available knowledge with the latest data. Methodology: English-language literature published between April 2000 and November 2023 (PubMed, NIH, Google Scholar) was analyzed for ocular complications of cCMV. The data obtained were categorized according to the ocular area involved and the incidence. A compilation of criteria for the symptomatic form of cCMV was also created. Results: The cCMV complications described in the literature affect all parts of the visual system: the anterior segment, the posterior segment, the posterior visual pathways, and the visual cortex. The most commonly described ocular complication of cCMV is choroidal and retinal scarring. Conclusions: Ophthalmic complications of cCMV can cause severe visual disturbances. Ophthalmic diagnosis in newborns should include hCMV PCR testing, which has the highest sensitivity and specificity. In the symptomatic form of cCMV, treatment should be instituted according to recommendations. A consensus should be established for screening of primary hCMV infection in pregnant women, the way in which to define the symptomatic form of cCMV, and the appropriateness and standards of treatment for primary hCMV infection in pregnant women.
- 8 June 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (12) , 3379
Open AccessOphthalmic Complications, Diagnosis, and Treatment of Congenital Human Cytomegalovirus Infection
Background: Human cytomegalovirus (hCMV) is the most common etiological agent of congenital infections seen in newborns. Among the most commonly observed complications in children with congenital human cytomegalovirus infection are those affecting the visual system. Ocular complications of congenital CMV (cCMV) are a topic rarely addressed in the literature, which prompted the authors to update the available knowledge with the latest data. Methodology: English-language literature published between April 2000 and November 2023 (PubMed, NIH, Google Scholar) was analyzed for ocular complications of cCMV. The data obtained were categorized according to the ocular area involved and the incidence. A compilation of criteria for the symptomatic form of cCMV was also created. Results: The cCMV complications described in the literature affect all parts of the visual system: the anterior segment, the posterior segment, the posterior visual pathways, and the visual cortex. The most commonly described ocular complication of cCMV is choroidal and retinal scarring. Conclusions: Ophthalmic complications of cCMV can cause severe visual disturbances. Ophthalmic diagnosis in newborns should include hCMV PCR testing, which has the highest sensitivity and specificity. In the symptomatic form of cCMV, treatment should be instituted according to recommendations. A consensus should be established for screening of primary hCMV infection in pregnant women, the way in which to define the symptomatic form of cCMV, and the appropriateness and standards of treatment for primary hCMV infection in pregnant women.
- Open Access
- 25 May 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (11) , 3097
Diagnosis and Treatment of Uveitis in Children: A Summary of the Latest Data from a 5-Year Literature Review (2018–2023)
Pediatric uveitis has a low incidence. It is very diverse in its presentation and is often the first sign of a severe systemic disease. The pediatric population poses a special therapeutic and diagnostic challenge due to the potentially adverse effects of therapeutic agents on the young body and difficult cooperation with the patient during the examination, as well as the increased risk of complications that can lead to severe disability. The most commonly diagnosed type of uveitis is non-infectious, with first-line therapy consisting of systemic corticosteroids followed by disease-modifying drugs (methotrexate (MTX), mycophenolate mofetil (MMF), and cyclosporin A (CsA)). In severe, refractory cases, biologic therapy is used. The authors reviewed the current literature on the etiology, diagnostic tools, and treatment of uveitis in the pediatric population covering the years 2018–2023, presenting current methods of modern diagnosis and treatment. The reason for writing this article was the need to update the knowledge on uveitis, driven by the increasing prevalence of autoimmune uveitis in the pediatric population. This trend presents significant challenges in diagnosing and treating the disease, as well as managing its complications. Correctly identifying the pathogenetic factor of uveitis can facilitate the diagnosis of the systemic disease underlying the ocular infection and enable the timely implementation of systemic treatment. Furthermore, the emergence of new diagnostic methods necessitates a revision and update of ophthalmic knowledge, essential for both ophthalmologists and other specialists involved in the treatment of uveitis.
- 25 May 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (11) , 3097
Open AccessDiagnosis and Treatment of Uveitis in Children: A Summary of the Latest Data from a 5-Year Literature Review (2018–2023)
Pediatric uveitis has a low incidence. It is very diverse in its presentation and is often the first sign of a severe systemic disease. The pediatric population poses a special therapeutic and diagnostic challenge due to the potentially adverse effects of therapeutic agents on the young body and difficult cooperation with the patient during the examination, as well as the increased risk of complications that can lead to severe disability. The most commonly diagnosed type of uveitis is non-infectious, with first-line therapy consisting of systemic corticosteroids followed by disease-modifying drugs (methotrexate (MTX), mycophenolate mofetil (MMF), and cyclosporin A (CsA)). In severe, refractory cases, biologic therapy is used. The authors reviewed the current literature on the etiology, diagnostic tools, and treatment of uveitis in the pediatric population covering the years 2018–2023, presenting current methods of modern diagnosis and treatment. The reason for writing this article was the need to update the knowledge on uveitis, driven by the increasing prevalence of autoimmune uveitis in the pediatric population. This trend presents significant challenges in diagnosing and treating the disease, as well as managing its complications. Correctly identifying the pathogenetic factor of uveitis can facilitate the diagnosis of the systemic disease underlying the ocular infection and enable the timely implementation of systemic treatment. Furthermore, the emergence of new diagnostic methods necessitates a revision and update of ophthalmic knowledge, essential for both ophthalmologists and other specialists involved in the treatment of uveitis.
- Open Access
- 27 February 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (5) , 1341
Isolated Depo-Medrol Administration under Tenon’s Capsule for Post-COVID-19 Uveitis in a Child: A Case Report and Literature Review
Coronavirus disease 2019 (COVID-19) can manifest with ocular symptoms. These symptoms can be divided into isolated events attributed to COVID-19, and those occurring in multisystem inflammatory syndrome in children (MIS-C), a newly diagnosed disease entity associated with COVID-19 infection. Currently, the literature lacks specific guidelines and treatment regimens for COVID-19 ocular symptoms, especially in children. The authors present the case of a 14-and-a-half-year-old boy with bilateral uveitis of the anterior and posterior segments along with vasculitis and optic neuritis associated with SARS-CoV-2 infection. The authors also perform an up-to-date review of all available publications on the treatment of post-COVID-19 uveitis in children described in the literature between 2020 and 2023. In the case described by the authors, the treatment involved a Depo-Medrol 40 mg/mL injection uder the Tenon capsule, with two subconjunctival injections of epinephrine, topical steroid therapy and non-steroidal anti-inflammatory drugs: dexamethasone 0.1%; diclofenac eye drops. In addition, acetylsalicylic acid (150 mg) and pentoxifylline (100 mg, orally) were administered throughout the course of the disease as well as up to 12 months after its termination, until a complete improvement in visual acuity and the withdrawal of ocular lesions were achieved. It can be assumed that this type of treatment is far more beneficial for pediatric patients, with an effect comparable to systemic steroid administration with a preserved improvement in retinal-vascular circulation, without exposing the child to systemic post-steroid complications.
- 27 February 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (5) , 1341
Open AccessIsolated Depo-Medrol Administration under Tenon’s Capsule for Post-COVID-19 Uveitis in a Child: A Case Report and Literature Review
Coronavirus disease 2019 (COVID-19) can manifest with ocular symptoms. These symptoms can be divided into isolated events attributed to COVID-19, and those occurring in multisystem inflammatory syndrome in children (MIS-C), a newly diagnosed disease entity associated with COVID-19 infection. Currently, the literature lacks specific guidelines and treatment regimens for COVID-19 ocular symptoms, especially in children. The authors present the case of a 14-and-a-half-year-old boy with bilateral uveitis of the anterior and posterior segments along with vasculitis and optic neuritis associated with SARS-CoV-2 infection. The authors also perform an up-to-date review of all available publications on the treatment of post-COVID-19 uveitis in children described in the literature between 2020 and 2023. In the case described by the authors, the treatment involved a Depo-Medrol 40 mg/mL injection uder the Tenon capsule, with two subconjunctival injections of epinephrine, topical steroid therapy and non-steroidal anti-inflammatory drugs: dexamethasone 0.1%; diclofenac eye drops. In addition, acetylsalicylic acid (150 mg) and pentoxifylline (100 mg, orally) were administered throughout the course of the disease as well as up to 12 months after its termination, until a complete improvement in visual acuity and the withdrawal of ocular lesions were achieved. It can be assumed that this type of treatment is far more beneficial for pediatric patients, with an effect comparable to systemic steroid administration with a preserved improvement in retinal-vascular circulation, without exposing the child to systemic post-steroid complications.
- Open Access
- 25 January 2024
- Published by MDPI AG in Preprints.org
Current Literature Review of COVID Eye Infections in the Pediatric Population and the Beneficial Effect of Isolated Treatment of COVID Uveitis (Panuveitis) in a Child after Isolated Administration of Depomedrol under the Tenon Capsule — a Case Report
Coronavirus disease 2019 (COVID-19), can manifest with ocular symptoms. These symptoms can be divided into isolated events attributed to COVID-19 and those occurring in multisystem inflammatory syndrome in children (MIS-C), a newly diagnosed disease entity associated with COVID-19 infection. Currently, the literature lacks specific guidelines and treatment regimens for COVID-19 ocular symptoms, especially in children.
- 25 January 2024
- Published by MDPI AG in Preprints.org
Open AccessCurrent Literature Review of COVID Eye Infections in the Pediatric Population and the Beneficial Effect of Isolated Treatment of COVID Uveitis (Panuveitis) in a Child after Isolated Administration of Depomedrol under the Tenon Capsule — a Case Report
Coronavirus disease 2019 (COVID-19), can manifest with ocular symptoms. These symptoms can be divided into isolated events attributed to COVID-19 and those occurring in multisystem inflammatory syndrome in children (MIS-C), a newly diagnosed disease entity associated with COVID-19 infection. Currently, the literature lacks specific guidelines and treatment regimens for COVID-19 ocular symptoms, especially in children.